

Experience of Izatizon application for male uresis system treatment under viral and inflammatory diseases

Zhyrun Y.V., Miroshkin V.O., Zhyrun V.N., Feldman M.Y., Ostapovich Y.M.

Road hospital №2 of the Stryy station, Stryy, Lviv's region, Ukraine

Medical collective of the urological department of the road hospital №2 of the Stryy station use preparation "izatizon" for prostate and urethra inflammatory diseases treatment and also they use it like antiviral and antitumoral preparation during the last 5 years.

Chronic prostatitis is one of the most diffuse diseases of the male urinary and sexual systems. Information about its treatment has been well known since ancient times but still we cannot answer exactly on all the questions of the disease pathogenesis and its treatment. The search of new means for prostate inflammatory disease therapy is one of the main tasks of modern urology.

Izatizon is one of the most perspective preparations that is able to increase specific and nonspecific resistance indexes during immune status violations and possesses antiseptic and antiphlogistic characteristics. Preparation action is based on good penetration through demytilsulfoxide (izatizon component) mucous membranes and transferring of other components (methisazone, twin) to the organism tissues. Izatizon components possess antiviral, antiphlogistic, antihistaminic, analgesic, antimicrobial and fibrinolytic characteristics. Moreover, the preparation is able to restore antimicrobial antibiotic activity against resistant or weakly sensible to it bacteria strains.

Izatizon tests were held in practice in the urological department of the road hospital №2 of the Stryy station. The research program includes gathering of complaints, anamnesis, physical examination, clinical analysis, prostate secreta examination, instrumental examination: ultrasonic diagnostics and cystoscopy. The preparation was used as a microclyster 30-50% of water solution or together with 10 ml. 2% of lidocain, once or twice a day during ten days.

The preparation was used for the treatment of 40 patients with acute attack of chronic prostatitis in complex with regular therapy. Except this, another (control) group (30 men) was observed. They were treated during the acute attack of chronic prostatitis only with habitual antiphlogistic therapy. Then the results of both groups were compared.

Improvement of health, symptomatology decrease, clinical analysis improvement were observed on the 4-6 day of the therapy in the patients group which was treated with izatizon, while in the control group the same result was observed on the average 7-10 day of the treatment. Relying on this it became possible to reduce antibacterial preparation application together with izatizon to 7-10 days. Antibiotic therapy average course in the control group was 14 days.

While the patients examination during the whole year, repeated prostatitis exacerbations were observed three times (3 persons) in the first group, that was 7,5%, and five times (5 persons) in the second group, that was 16,7%. Izatizon

microclysters were used to treat the disease relapses in the first patients group, their condition became stabilized and in the control group, we had to use antibiotic therapy.

Among preparation side effects, the most common is burning feeling in the application area. The addition of 2%-6-10 ml. of lidocaine solution was successfully used against this defect. It removed or reduced significantly side effects and did not influence the treatment course.

Except izatizon application for prostatitis treatment, it was also widely used against pointed condyloma. We have treatment experience of 10 patients and the obtained results were good. Izatizon was applied as applique on condyloma three times a day as a result condylomas of six patients have disappeared and have significantly decreased on the rest of the patients.

Based on previously mentioned we can claim about positive effect of “izatizon” application during prostate inflammatory disease treatment and pointed condylomas. It also decreases antibacterial preparation usage, prolongs relapse-free clinical course and it can be introduced for public application.

Literature

1. Dzyurak V.S et al. “Chronic prostatitis” – Kyiv, 2003.
2. Lipshulz L et al. “Urology for common practice doctors” – Saint Petersburg, 1997
3. Lozyuk L.V. et al. “Medicaments therapy and viral diseases prevention” – Lviv, 2003
4. Lopatkin N.A. “Urological guide” – Moscow, 1978